CITATION REPORT List of articles citing



DOI: 10.1007/s00262-006-0180-4 Cancer Immunology, Immunotherapy, 2007, 56, 303-317.

Source: https://exaly.com/paper-pdf/43078166/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
298	Display technologies: application for the discovery of drug and gene delivery agents. 2006 , 58, 1622-54		194
297	A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. 2007 , 20, 569-76		92
296	Engineering antibodies for clinical applications. 2007 , 25, 307-16		93
295	Properties, production, and applications of camelid single-domain antibody fragments. 2007 , 77, 13-22		557
294	When binding is enough: nonactivating antibody formats. 2008 , 20, 479-85		81
293	SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. <i>Molecular Imaging and Biology</i> , 2008 , 10, 167-75	3.8	140
292	Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. 2008 , 49, 788-95		169
291	High-expression of monoclonal nanobodies used in the preparation of HRP-conjugated second antibody. 2008 , 27, 269-76		5
290	New frontiers in nanotechnology for cancer treatment. 2008 , 26, 74-85		233
289	Production and characterization of a high-affinity nanobody against human endoglin. 2008 , 27, 353-60		15
288	Single-domain antibodies as building blocks for novel therapeutics. 2008 , 8, 600-8		157
287	Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2288-97	6.1	219
286	Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. 2008 , 82, 12069-81		93
285	EGF induces coalescence of different lipid rafts. 2008 , 121, 2519-28		117
284	Recent advances in nanooncology. 2008 , 7, 1-13		49
283	[The future of antibody fragments, made of a single immunoglobulin domain]. 2009, 25, 1159-62		2
282	Isolation of novel EGFR-specific VHH domains. 2009 , 14, 77-85		16

281	Application of Nanobiotechnology in Cancer Therapeutics. 2009 , 245-268		2
280	EGF induces rapid reorganization of plasma membrane microdomains. 2009 , 2, 213-4		7
279	Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery. 2009 , 146, 867-	-74	14
278	Selection and characterization of KDEL-specific VHH antibody fragments and their application in the study of ER resident protein expression. <i>Journal of Immunological Methods</i> , 2009 , 342, 1-12	2.5	24
277	Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. 2009 , 198, 157-74		341
276	Transglutaminase-catalyzed covalent multimerization of Camelidae anti-human TNF single domain antibodies improves neutralizing activity. 2009 , 142, 170-8		25
275	Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. 2009 , 18, 81-100		46
274	High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis. 2009 , 15, 1259-68		40
273	Pharmaceutical Perspectives of Cancer Therapeutics. 2009,		11
272	Reverse proteomic antibody screening identifies anti adhesive VHH targeting VLA-3. <i>Molecular Immunology</i> , 2009 , 46, 2022-8	4.3	9
271	Engineered affinity proteins for tumour-targeting applications. <i>Biotechnology and Applied Biochemistry</i> , 2009 , 53, 1-29	2.8	58
270	Targeting the EGF receptor ectodomain in the context of cancer. 2009 , 13, 1347-61		1
269	Strategies to extend plasma half-lives of recombinant antibodies. <i>BioDrugs</i> , 2009 , 23, 93-109	7.9	160
268	Single-Domain Antibodies. 216-230		
267	Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. 2009 , 9, 748-60		140
266	Nanobodies□ : proficient tools in diagnostics. 2010 , 10, 777-85		63
265	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. 2010 , 145, 165-75		99
264	COMBODY: one-domain antibody multimer with improved avidity. 2010 , 88, 667-75		30

263	Nanobodies, Single-Domain Antigen-Binding Fragments of Camelid Heavy-Chain Antibodies. 2010 , 29-48	11
262	Isolation of a Novel Nanobody Against HER-2/neuUsing Phage Displays Technology. 2010 , 41, 69-76	2
261	CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. 2010 , 107, 20565-70	174
260	A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire. <i>Journal of Immunology</i> , 2010 , 184, 5696-704	52
259	Differential tumor-targeting abilities of three single-domain antibody formats. 2010 , 289, 81-90	91
258	Biofunctional TiO2 nanoparticle-mediated photokilling of cancer cells using UV irradiation. 2010 , 1, 209	23
257	Nanobiosensing for Clinical Diagnosis. 2011 , 535-567	3
256	Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. <i>PLoS ONE</i> , 2011 , 6, e17665	121
255	Single-domain llama antibodies as specific intracellular inhibitors of SpvB, the actin ADP-ribosylating toxin of Salmonella typhimurium. <i>FASEB Journal</i> , 2011 , 25, 526-34	31
254	Engineering antibodies for cancer therapy. 2011 , 2, 53-75	23
253	Diagnostic evaluation of a nanobody with picomolar affinity toward the protease RgpB from Porphyromonas gingivalis. 2011 , 415, 158-67	25
252	Camel nanoantibody is an efficient tool for research, diagnostics and therapy. 2011 , 45, 66-73	29
251	Isolation of functional single domain antibody by whole cell immunization: implications for cancer treatment. <i>Journal of Immunological Methods</i> , 2011 , 371, 70-80	15
250	Strategies for extended serum half-life of protein therapeutics. 2011 , 22, 868-76	360
249	The development of activating and inhibiting camelid VHH domains against human protein kinase C epsilon. 2011 , 42, 332-9	12
248	Nanobodies□: new ammunition to battle viruses. 2011 , 92, 389-407	96
247	Nanobody; an old concept and new vehicle for immunotargeting. 2011 , 40, 299-338	78
246	Bispecific Antibodies: Developments and Current Perspectives. 2011 , 1-28	3

(2012-2011)

245	Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. <i>Molecular Imaging and Biology</i> , 2011 , 13, 940-8	46
244	Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. 2011 , 38, 753-63	79
243	HIV sexual transmission and microbicides. 2011 , 21, 110-33	40
242	Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. 2011 , 6, 85-92	85
241	A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. 2011 , 129, 2013-24	162
240	Bispecific Single Domain Antibodies. 2011 , 101-114	1
239	Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. 2011 , 203, 1063-72	68
238	Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2. 2012 , 1, 34	8
237	Fundamental technologies for antibody engineering. 2012 , 57-595	
236	Sources of antibody variable chains. 2012 , 77-595	
235	Development issues: antibody stability, developability, immunogenicity, and comparability. 2012, 377-595	5
234	Therapeutic antibody classes. 2012 , 197-595	1
233	Monoclonal antibody targets and mechanisms of action. 2012 , 163-595	1
232	Cell line development. 2012 , 421-595	1
231	Introduction to biologics and monoclonal antibodies. 2012 , 1-595	2
230	Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins. 2012, 15-595	
229	Antibody Fc engineering for optimal antibody performance. 2012 , 225-595	
228	Antibody structurefunction relationships. 2012 , 37-595	

227	Issues facing therapeutic monoclonal antibodies for the future. 2012 , 439-595		1
226	Antibody-drug conjugates. 2012 , 345-595		2
225	Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. 2012 , 109, 16642-7		59
224	Antibody interactions with the immune system. 2012 , 131-595		
223	IgG glycans and glyco-engineering. 2012 , 251-595		
222	Antibody fragments as therapeutics. 2012 , 265-595		1
221	Multiple antibody and multi-specificity approaches. 2012 , 299-595		
220	FcFPs and similar constructs using Fc. 2012 , 329-595		
219	Interactions of human IgGs with non-human systems. 2012 , 405-595		
218	Variable chain engineering [humanization and optimization approaches. 2012 , 111-595		
217	Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent Anti E pidermal Growth Factor Receptor Nanobody. 2012 , 11, 7290.2011.00025		119
216	AlbudAblTechnology PlatformVersatile Albumin Binding Domains for the Development of Therapeutics with Tunable Half-Lives. 2012 , 249-268		3
215	A high-affinity gold-binding camel antibody: antibody engineering for one-pot functionalization of gold nanoparticles as biointerface molecules. 2012 , 23, 1934-44		26
214	Selection by phage display of single domain antibodies specific to antigens in their native conformation. <i>Methods in Molecular Biology</i> , 2012 , 911, 81-104	1.4	9
213	Half-Life Extension by Binding to Albumin through an Albumin Binding Domain. 2012, 269-283		12
212	Molecular imaging using Nanobodies: a case study. <i>Methods in Molecular Biology</i> , 2012 , 911, 559-67	1.4	13
211	Selection of VHH antibody fragments that recognize different Aldepositions using complex immune libraries. <i>Methods in Molecular Biology</i> , 2012 , 911, 241-53	1.4	4
210	Efficient heterologous expression and secretion in Aspergillus oryzae of a llama variable heavy-chain antibody fragment V(HH) against EGFR. 2012 , 96, 81-8		20

(2013-2012)

209	2012, 28, 198-205		25
208	Single Domain Antibodies. <i>Methods in Molecular Biology</i> , 2012 ,	1.4	10
207	Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting. 2012 , 31, 1015-26		16
206	In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. 2012 , 138, 1081-90		31
205	Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. 2012 , 45, 399-407		35
204	Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. <i>Molecular Immunology</i> , 2012 , 50, 35-41	4.3	79
203	Iron oxide nanoparticles for targeted cancer imaging and diagnostics. 2012 , 8, 275-90		247
202	Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. 2012 , 318, 1112-24		41
201	Immunoglobulin domains in Escherichia coli and other enterobacteria: from pathogenesis to applications in antibody technologies. 2013 , 37, 204-50		65
200	Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. 2013 , 40, 1718-29		92
199	Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment. 2013 , 91, 399-410		36
198	Albumin as a versatile platform for drug half-life extension. 2013 , 1830, 5526-34		280
197	Antigen Targeting to Dendritic Cells for Cancer Immunotherapy. 2013, 147-171		
196	Application of 300lenhanced fluorescence on a plasmonic chip modified with a bispecific antibody to a sensitive immunosensor. 2013 , 5, 8628-32		35
195	Keratinocyte growth factor phage model peptides can promote human oral mucosal epithelial cell proliferation. 2013 , 116, e92-7		3
194	The untapped potential of Gallium 68-PET: the next wave of G a-agents. 2013 , 76, 14-23		40
193	Selection of nanobodies that target human neonatal Fc receptor. Scientific Reports, 2013, 3, 1118	4.9	8
192	Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody. 2013 , 40, 6737-45		24

191	High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli. 2013 , 12, 97		54
190	Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. 2013, 21, 1214-24		135
189	Targeting tumors with nanobodies for cancer imaging and therapy. 2013 , 172, 607-17		146
188	Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). 2013 , 97, 245-54		23
187	Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity. 2013 , 97, 8547-58		8
186	Nanobodies and their potential applications. <i>Nanomedicine</i> , 2013 , 8, 1013-26	5.6	183
185	Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. 2013 , 40, 52-9		67
184	Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. 2013 , 288, 29562-72		110
183	Methodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies. 2013 , 33, 40-8		5
182	Novel therapy based on camelid nanobodies. 2013 , 4, 1321-36		28
181	Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function. 2013 , 288, 25173-25182		32
180	Generation of single-domain antibody multimers with three different self-associating peptides. 2013 , 26, 417-23		13
179	Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif. 2013 , 126, 4900-12		46
178	Single domain antibody multimers confer protection against rabies infection. <i>PLoS ONE</i> , 2013 , 8, e71383	3.7	11
177	Nanobodies as novel agents for disease diagnosis and therapy. <i>International Journal of Nanomedicine</i> , 2013 , 8, 4215-27	7.3	85
176	A nanobody-based method for tracking factor XII activation in plasma. 2013 , 110, 458-68		30
175	Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody. 2014 , 134, 2663-73		66
174	Nanobodies and nanocrystals: highly sensitive quantum dot-based homogeneous FRET immunoassay for serum-based EGFR detection. <i>Small</i> , 2014 , 10, 734-40	11	87

173	Individualizing breast cancer treatment-The dawn of personalized medicine. 2014, 320, 1-11		24
172	Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer. 2014 , 15, 709-21		69
171	A general protocol for the generation of Nanobodies for structural biology. 2014 , 9, 674-93		380
170	EGF receptor-targeting peptide conjugate incorporating a near-IR fluorescent dye and a novel 1,4,7-triazacyclononane-based (64)Cu(II) chelator assembled via click chemistry. 2014 , 25, 1011-22		20
169	Engineered Antibody Domains as Candidate Therapeutics. 2014 , 487-518		
168	Generation of Immune Globulin Single Variable Domains by Display Technologies. 2014 , 291-302		1
167	Selection and identification of single-domain antibody fragment against capsid protein of porcine circovirus type 2 (PCV2) from C. bactrianus. 2014 , 160, 12-9		14
166	Irreversible site-specific hydrazinolysis of proteins by use of sortase. <i>Angewandte Chemie - International Edition</i> , 2014 , 53, 2198-202	16.4	97
165	Irreversible Site-Specific Hydrazinolysis of Proteins by Use of Sortase. <i>Angewandte Chemie</i> , 2014 , 126, 2230-2234	3.6	19
164	Camelid heavy chain only antibody fragment domain against Eite of amyloid precursor protein cleaving enzyme 1 inhibits Elecretase activity in vitro and in vivo. <i>FEBS Journal</i> , 2015 , 282, 3618-31	5.7	8
163	Development of a bispecific antibody tetramerized through hetero-associating peptides. <i>FEBS Journal</i> , 2015 , 282, 4389-401	5.7	8
162	Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy. 2015 , 2, 15003		18
161	Role of ErbB Receptors in Cancer Cell Migration and Invasion. Frontiers in Pharmacology, 2015 , 6, 283	5.6	169
160	A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting. <i>International Journal of Nanomedicine</i> , 2015 , 10, 2857-69	7.3	9
159	The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery. 2015 , 211, 144-62		107
158	A homogeneous time-resolved fluorescence-based high-throughput screening for discovery of inhibitors of Nef-sdAb19 interaction. 2015 , 47, 1485-93		2
157	Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action. 2015 , 87, 251-62		52
156	Nanobody-based cancer therapy of solid tumors. <i>Nanomedicine</i> , 2015 , 10, 161-74	5.6	155

155	Characterization and evaluation of the artemis camera for fluorescence-guided cancer surgery. <i>Molecular Imaging and Biology</i> , 2015 , 17, 413-23	3.8	33
154	Selection and Characterization of Specific Nanobody Against Human Immunoglobulin G. 2015 , 34, 201-5	5	14
153	Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator. <i>Molecular Immunology</i> , 2015 , 65, 384-90	4.3	7
152	Albumin and its application in drug delivery. 2015 , 12, 793-812		191
151	Engineering toxin-resistant therapeutic stem cells to treat brain tumors. 2015 , 33, 589-600		24
150	The Past, Current Studies and Future of Organometallic 99mTc(CO)3 Labeled Peptides and Proteins. 2016 , 22, 4854-4867		10
149	Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features. 2016 , 149, 111-21		8
148	Highly specific and potently activating VØVØ-T cell specific nanobodies for diagnostic and therapeutic applications. 2016 , 169, 128-138		22
147	High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement. 2016 , 291, 15243-55		14
146	Nanobodies as therapeutics: big opportunities for small antibodies. 2016 , 21, 1076-113		221
145	Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 138, 1414-1423.e9	11.5	111
144	High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display. 2016 , 8, 1286-1301		19
143	Characterization and Selection of 3-(1-Naphthoyl)-Indole Derivative-Specific Alpaca VHH Antibodies Using a Phage Display Library. 2016 , 35, 231-4		3
142	Nanobodies and Antibodies for Duplexed EGFR/HER2 Immunoassays Using Terbium-to-Quantum Dot FRET. 2016 , 28, 8256-8267		39
141	Recent progress in protein-protein interaction study for EGFR-targeted therapeutics. 2016 , 13, 817-32		10
140	Endogenous DKK1 and FRZB Regulate Chondrogenesis and Hypertrophy in Three-Dimensional Cultures of Human Chondrocytes and Human Mesenchymal Stem Cells. 2016 , 25, 1808-1817		22
139	Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy. <i>Scientific Reports</i> , 2016 , 6, 31621	4.9	14
138	Time-gated FRET nanoassemblies for rapid and sensitive intra- and extracellular fluorescence imaging. 2016 , 2, e1600265		45

137	Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. <i>Scientific Reports</i> , 2016 , 6, 28643	18
136	Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer. 2016 , 8, 40-48	123
135	Incorporation of a Doubly Functionalized Synthetic Amino Acid into Proteins for Creating Chemical and Light-Induced Conjugates. 2016 , 27, 198-206	30
134	Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics. 2016 , 29, 123-33	9
133	A rigidified AAZTA-like ligand as efficient chelator for 68Ga radiopharmaceuticals. 2016 , 1, 163-171	10
132	Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer. <i>Molecular Imaging and Biology</i> , 2016 , 18, 535-44	45
131	Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors. 2016 , 8, 678-88	6
130	Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR). <i>Protein Expression and Purification</i> , 2016 , 120, 59-64	10
129	Joining the in vitro immunization of alpaca lymphocytes and phage display: rapid and cost effective pipeline for sdAb synthesis. 2017 , 16, 13	11
128	Self-Assembling VHH-Elastin-Like Peptides for Photodynamic Nanomedicine. 2017 , 18, 1302-1310	28
127	Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A. 2017 , 28, 263-270	7
126	Prevention of VÐVØ T Cell Activation by a VÐVØ TCR Nanobody. <i>Journal of Immunology</i> , 2017 , 198, 308-317	8
125	Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K Polymorphism. 2017 , 77, 1188-1199	53
124	Legomedicine-A Versatile Chemo-Enzymatic Approach for the Preparation of Targeted Dual-Labeled Llama Antibody-Nanoparticle Conjugates. 2017 , 28, 539-548	29
123	A Conjugate of an Anti-Epidermal Growth Factor Receptor (EGFR) VHH and a Cell-Penetrating Peptide Drives Receptor Internalization and Blocks EGFR Activation. 2017 , 18, 2390-2394	16
122	Nanofitin as a New Molecular-Imaging Agent for the Diagnosis of Epidermal Growth Factor Receptor Over-Expressing Tumors. 2017 , 28, 2361-2371	16
121	Structural insights into a high affinity nanobody:antigen complex by homology modelling. 2017 , 76, 305-312	7
120	Escherichia coli surface display for the selection of nanobodies. 2017 , 10, 1468-1484	35

119	CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome. 2017 , 363, 35-44		24
118	Therapeutic Agents That Inhibit Angiogenesis. 2017 , 757-769		
117	Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics. <i>Frontiers in Immunology</i> , 2017 , 8, 1603	8.4	233
116	Single Domain Antibodies as New Biomarker Detectors. 2017 , 7,		16
115	Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview. <i>Frontiers in Immunology</i> , 2017 , 8, 865	8.4	44
114	Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine-Nanobody Complex. <i>Frontiers in Immunology</i> , 2017 , 8, 884	8.4	21
113	Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy. <i>Frontiers in Immunology</i> , 2017 , 8, 1442	8.4	83
112	Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers. <i>Frontiers in Immunology</i> , 2017 , 8, 1746	8.4	33
111	Soluble Expression in Escherichia coli of a Single-Domain Antibody-Tumor Necrosis Factor F usion Protein Specific for Epidermal Growth Factor Receptor. 2018 , 37, 20-25		2
110	Transglutaminase mediated PEGylation of nanobodies for targeted nano-drug delivery. 2018 , 6, 1011-	1017	22
109	Targeted and theranostic applications for nanotechnologies in medicine. 2018, 399-511		3
108	The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates. 2018 , 124, 63-72		23
107	Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. 2018 , 26, 1939-1949		26
106	ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. 2017 , 7, e1377874		41
105	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of VBVI-T cells. 2017 , 7, e1375641		34
104	Application of camelid heavy-chain variable domains (VHHs) in prevention and treatment of bacterial and viral infections. 2018 , 37, 69-76		12
103	Modular Pore-Forming Immunotoxins with Caged Cytotoxicity Tailored by Directed Evolution. 2018 , 13, 3153-3160		13
102	Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector. 2018 , 11, 751		6

101	Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function. 2018, 31, 301-312		5
100	Use, Applications and Mechanisms of Intracellular Actions of Camelid VHHs. 2018,		2
99	The Development of Single Domain Antibodies for Diagnostic and Therapeutic Applications. 2018,		3
98	From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells and. <i>Oncotarget</i> , 2018 , 9, 25597-25616	3.3	38
97	Compact Seahorse-Shaped Ticellactivating Antibody for Cancer Therapy. <i>Advanced Therapeutics</i> , 2018 , 1, 1700031	4.9	3
96	Novel Constructs⊞alf-Life Extensions. AAPS Advances in the Pharmaceutical Sciences Series, 2018, 527-54	16 .5	1
95	Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment. <i>Frontiers in Immunology</i> , 2018 , 9, 273	8.4	46
94	A bispecific antibody strategy to target multiple type 2 cytokines in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 1185-1193.e4	11.5	19
93	Nanobodies and Their In Vivo Applications. 2019 , 263-277		0
92	Site-Specific Encoding of Photoactivity in Antibodies Enables Light-Mediated Antibody Antigen Binding on Live Cells. <i>Angewandte Chemie</i> , 2019 , 131, 18154-18161	3.6	6
91	Site-Specific Encoding of Photoactivity in Antibodies Enables Light-Mediated Antibody-Antigen Binding on Live Cells. <i>Angewandte Chemie - International Edition</i> , 2019 , 58, 17986-17993	16.4	18
90	Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies. <i>Chemical Science</i> , 2019 , 10, 9331-9338	9.4	11
89	Fusion with an albumin-binding domain improves pharmacokinetics of an #B-integrin binding fibronectin scaffold protein. <i>Biotechnology and Applied Biochemistry</i> , 2019 , 66, 617-625	2.8	6
88	Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival. <i>Journal of Cellular Biochemistry</i> , 2019 , 120, 18077-18087	4.7	19
87	Targeting RyR2 with a phosphorylation site-specific nanobody reverses dysfunction of failing cardiomyocytes in rats. <i>FASEB Journal</i> , 2019 , 33, 7467-7478	0.9	2
86	Imaging of Tumor Spheroids, Dual-Isotope SPECT, and Autoradiographic Analysis to Assess the Tumor Uptake and Distribution of Different Nanobodies. <i>Molecular Imaging and Biology</i> , 2019 , 21, 1079-	- 1 088	17
85	Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases. <i>Antibodies</i> , 2019 , 8,	7	23
84	Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations. <i>Current Medicinal Chemistry</i> , 2019 , 26, 396-426	4.3	32

83	Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling. <i>Biochemical Journal</i> , 2019 , 476, 39-50	3.8	10
82	Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 100-111	6.1	9
81	Anti-TTR Nanobodies Allow the Identification of TTR Neuritogenic Epitope Associated with TTR-Megalin Neurotrophic Activities. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 704-715	5.7	4
80	Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug. <i>Nano Letters</i> , 2019 , 19, 247-254	11.5	44
79	The Therapeutic Potential of Nanobodies. <i>BioDrugs</i> , 2020 , 34, 11-26	7.9	206
78	Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging. <i>Small</i> , 2020 , 16, e1905013	11	10
77	Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy. <i>Cancers</i> , 2020 , 12,	6.6	5
76	Nanobodies in cancer. <i>Seminars in Immunology</i> , 2021 , 52, 101425	10.7	4
75	Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. <i>Frontiers in Oncology</i> , 2020 , 10, 1182	5.3	58
74	Optogenetic control of protein binding using light-switchable nanobodies. <i>Nature Communications</i> , 2020 , 11, 4044	17.4	43
73	Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy. <i>International Journal of Nanomedicine</i> , 2020 , 15, 8201-8215	7.3	21
72	An Inside Job: Applications of Intracellular Single Domain Antibodies. <i>Biomolecules</i> , 2020 , 10,	5.9	9
71	Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. <i>Frontiers in Immunology</i> , 2020 , 11, 810	8.4	5
70	Research Article Nanobodies and their medical applications. <i>Genetics and Molecular Research</i> , 2020 , 19,	1.2	1
69	Site-specific functionality and tryptophan mimicry of lipidation in tetraspanin CD9. <i>FEBS Journal</i> , 2020 , 287, 5323-5344	5.7	6
68	Targeted Delivery of In Into the Nuclei of EGFR Overexpressing Cells Modular Nanotransporters With Anti-EGFR Affibody. <i>Frontiers in Pharmacology</i> , 2020 , 11, 176	5.6	9
67	Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement. <i>Molecular Immunology</i> , 2020 , 124, 200-210	4.3	5
66	Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. <i>Biomolecules</i> , 2020 , 10,	5.9	2

(2021-2020)

65	Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens. <i>Pharmacological Research</i> , 2020 , 156, 104790	10.2	14
64	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes VØVØ T cell-Mediated Antitumor Responses in Human B-cell Malignancies. <i>Cancer Immunology Research</i> , 2021 , 9, 50-61	12.5	5
63	EGFR and anti-EGFR nanobodies: review and update. Journal of Drug Targeting, 2021, 29, 387-402	5.4	7
62	Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tumors. <i>Cancers</i> , 2021 , 13,	6.6	4
61	Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy. <i>International Journal of Nanomedicine</i> , 2021 , 16, 2337-2356	7.3	16
60	Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody". <i>Molecular Biotechnology</i> , 2021 , 63, 525-533	3	2
59	The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors. <i>Beilstein Journal of Nanotechnology</i> , 2021 , 12, 375-401	3	1
58	Nanobodies as probes to investigate purinergic signaling. <i>Biochemical Pharmacology</i> , 2021 , 187, 114394	16	3
57	CPPs to the Test: Effects on Binding, Uptake and Biodistribution of a Tumor Targeting Nanobody. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	3
56	Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study. <i>Biomolecules</i> , 2021 , 11,	5.9	1
55	Single-domain antibodies for targeting, detection and in vivo imaging of human CD4+ cells.		1
54	A comparative study and evaluation of anti-EGFR nanobodies expressed in Pichia pastoris and Escherichia coli as antitumor moieties. <i>Protein Expression and Purification</i> , 2021 , 184, 105888	2	0
53	An integrated computational pipeline for designing high-affinity nanobodies with expanded genetic codes. <i>Briefings in Bioinformatics</i> , 2021 , 22,	13.4	1
52	TRIM28 Selective Nanobody Reduces Glioblastoma Stem Cell Invasion. <i>Molecules</i> , 2021 , 26,	4.8	2
51	Nanobody-targeted photodynamic therapy for the treatment of feline oral carcinoma: a step towards translation to the veterinary clinic. <i>Nanophotonics</i> , 2021 , 10, 3075-3087	6.3	2
50	Application of lanthanide-doped upconversion nanoparticles for cancer treatment: a review. <i>Nanomedicine</i> , 2021 , 16, 2207-2242	5.6	5
49	Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
48	Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation. <i>Journal of Inorganic Biochemistry</i> , 2021 , 223, 111553	4.2	2

47	Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR. <i>Frontiers in Immunology</i> , 2020 , 11, 614363	8.4	1
46	Nanobody-siRNA Conjugates for Targeted Delivery of siRNA to Cancer Cells. <i>Molecular Pharmaceutics</i> , 2021 , 18, 1048-1060	5.6	5
45	Pre-clinical development of fluorescent tracers and translation towards clinical application. 2021,		
44	Shark novel antigen receptorsthe next generation of biologic therapeutics?. <i>Advances in Experimental Medicine and Biology</i> , 2009 , 655, 49-62	3.6	31
43	Systems Biology and Nanotechnology. 2008 , 1411-1433		1
42	Optogenetic control of protein binding using light-switchable nanobodies.		5
41	Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH. <i>PLoS ONE</i> , 2011 , 6, e26299	3.7	18
40	Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. <i>PLoS ONE</i> , 2012 , 7, e33298	3.7	50
39	Expression cloning of camelid nanobodies specific for Xenopus embryonic antigens. <i>PLoS ONE</i> , 2014 , 9, e107521	3.7	3
38	Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro. <i>Oncotarget</i> , 2017 , 8, 38568-38580	3.3	21
37	Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2020 , 15, 200-211	2.6	2
36	Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017 , 17, 301-308	2.2	29
35	References. 2012 , 459-595		1
34	Targeting RyR2 with a phosphorylation site-specific nanobody Reverses Dysfunction of Failing Cardiomyocytes in Rat.		
33	Enzymatic ligation of an antibody and arginine 9 peptide for efficient and cell-specific siRNA delivery. <i>Scientific Reports</i> , 2021 , 11, 21882	4.9	О
32	Novel Ion Channel Targets and Drug Delivery Tools for Controlling Glioblastoma Cell Invasiveness. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
31	Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3). <i>Iranian Journal of Basic Medical Sciences</i> , 2016 , 19, 1201-1208	1.8	23
30	Induction of PI3K/Akt-Mediated Apoptosis in Osteoclasts Is a Key Approach for Pills to Treat Osteonecrosis of the Femoral Head <i>Frontiers in Pharmacology</i> , 2021 , 12, 729909	5.6	1

29	EGFR-Targeted Photodynamic Therapy Pharmaceutics, 2022, 14,	6.4	6
28	Nanobody-based microfluidic human Fc assay for preclinical plasma quantification of IgG1/1.1 and IgG1-Fc-conjugates <i>Journal of Immunological Methods</i> , 2022 , 502, 113214	2.5	O
27	Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates <i>International Immunopharmacology</i> , 2022 , 105, 108585	5.8	O
26	Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications <i>Methods in Molecular Biology</i> , 2022 , 2446, 3-17	1.4	O
25	Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody <i>BMC Molecular and Cell Biology</i> , 2022 , 23, 12	2.7	O
24	Single-Domain Antibodies for Targeting, Detection, and Imaging of Human CD4 Cells <i>Frontiers in Immunology</i> , 2021 , 12, 799910	8.4	Ο
23	OUP accepted manuscript. Burns and Trauma,	5.3	O
22	Monitoring Extracellular Ion and Metabolite Dynamics with Recombinant Nanobody-Fused Biosensors. SSRN Electronic Journal,	1	
21	Monitoring extracellular ion and metabolite dynamics with recombinant nanobody-fused biosensors.		
20	Multifaceted Activities of Seven Nanobodies against Complement C4b <i>Journal of Immunology</i> , 2022 ,	5.3	1
19	DataSheet_1.pdf. 2021 ,		
18	Image_1.jpg. 2020 ,		
17	Image_2.jpg. 2020 ,		
16	Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein <i>Iranian Journal of Basic Medical Sciences</i> , 2021 , 24, 1726-1733	1.8	
15	Optogenetic technologies in translational cancer research. <i>Biotechnology Advances</i> , 2022 , 60, 108005	17.8	
14	Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies. 2022 , 12,		
13	Nanobodies; new molecular instruments with special specifications for targeting, diagnosis and treatment of triple-negative breast cancer. 2022 , 22,		О
12	Monitoring extracellular ion and metabolite dynamics with recombinant nanobody-fused biosensors. 2022 , 25, 104907		O

11	Molecular basis for thermal stability and affinity in a VHH: contribution of the framework region and its influence in the conformation of the CDR3.	О
10	Camels biological fluids contained nanobodies: promising avenue in cancer therapy. 2022 , 22,	O
9	Evolving therapeutic proteins to precisely kill cancer cells. 2022, 351, 779-804	O
8	Generation of a Single-Domain Antibody against Isolated Escherichia Coli that Causes Camel-Calf Death. 2021 , 2, 6-16	O
7	Fluorescently tagged nanobodies and NanoBRET to study ligand-binding and agonist-induced conformational changes of full-length EGFR expressed in living cells. 13,	O
6	Innovative strategies to study epigenetic regulation and advance precision medicine. 2023,	O
5	Site-specific encoding of photoactivity and photoreactivity into antibody fragments.	О
4	Application Progress of the Single Domain Antibody in Medicine. 2023, 24, 4176	O
3	Statistical mining of triple-negative breast cancer-specific nanobodies among huge libraries from immunized alpacas.	O
2	Improvements in drug delivery and monitoring of diseases in biotherapeutics. 2020 , 6, 53-54	O
1	Statistical mining of triple-negative breast cancer-specific nanobodies among huge libraries from immunized alpacas.	О